3'-(Arylmethyl)- and 3'-(aryloxy)-3-phenyl-4-hydroxyquinolin-2(1H)-ones: orally active antagonists of the glycine site on the NMDA receptor.
Kulagowski
J J
JJ
Merck Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Terlings Park, Harlow, Essex, U.K.
Baker
R
R
Curtis
N R
NR
Leeson
P D
PD
Mawer
I M
IM
Moseley
A M
AM
Ridgill
M P
MP
Rowley
M
M
Stansfield
I
I
Foster
A C
AC
D000284:Administration, Oral; D000634:Aminoquinolines / Q000378:metabolism; D000818:Animals; D000927:Anticonvulsants / Q000494:pharmacology; D001665:Binding Sites / Q000187:drug effects; D001667:Binding, Competitive; D001812:Blood-Brain Barrier; D001921:Brain / Q000378:metabolism; D005998:Glycine / Q000037:antagonists & inhibitors*; D006912:Hydroxyquinolines / Q000138:chemical synthesis / Q000378:metabolism / Q000494:pharmacology*; D066298:In Vitro Techniques; D051379:Mice; D008811:Mice, Inbred DBA; D051381:Rats; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors* / Q000378:metabolism; D013329:Structure-Activity Relationship
D000634:Aminoquinolines; D000927:Anticonvulsants; D006912:Hydroxyquinolines; D016194:Receptors, N-Methyl-D-Aspartate; C074617:4-trans-2-carboxy-5,7-dichloro-4-phenylaminocarbonylamino-1,2,3,4-tetrahydroquinoline; D005998:Glycine